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Abstract 
 
The protein kinase B (PKB) family encompasses three isoforms; PKB (AKT1), 
PKB (AKT2) and PKB (AKT3). PKB and PKBbut not PKB, are prominently 
expressed in classical insulin-sensitive tissues like liver, muscle and fat. Transgenic 
mice deficient for PKB, PKB or PKB have been analysed to study the roles of 
PKB isoforms in metabolic regulation. Until recently, only loss of PKB was reported 
to result in metabolic disorders, especially insulin resistance, in humans and mice. 
However, a new study has shown that PKB-deficient mice show enhanced glucose 
tolerance accompanied by improved -cell function and higher insulin sensitivity in 
adipocytes. These findings prompted us to review the relevant literature on the 
regulation of glucose metabolism by PKB isoforms in liver, skeletal muscle, 
adipocytes and pancreas.  
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 Introduction 
The level of circulating glucose has to be adjusted to variations in food intake and 
energy demands, which is primarily regulated by the insulin/glucagon system in 
mammals. Insulin lowers blood glucose by increasing uptake and deposition into 
muscle and adipose tissue as well as by decreasing its release from the liver. 
Glucagon mainly acts on hepatocytes where it opposes the action of insulin and 
stimulates release of glucose into circulation. Insulin signalling targets various cell 
types in the whole organism and, in addition to its role in metabolism, affects cellular 
processes such as protein synthesis, proliferation and survival. Therefore a complex 
network of molecular pathways is required to transduce insulin signalling into cell 
type-specific and context-dependent responses. Protein kinase B (PKB) has been 
shown to be a key element in the insulin signal transduction network. 
The physiological and tissue-specific effects of the three PKB isoforms have been 
extensively studied in vitro but most comprehensively in transgenic mice. While 
Pkb -/- and Pkb -/- mice show impaired foetal growth and brain development, 
respectively, glucose homeostasis was found unaffected in both models (Chen et al., 
2001, Cho et al., 2001b, Easton et al., 2005, Tschopp et al., 2005, Yang et al., 2003). 
In contrast, Pkb -/- mice are insulin resistant, mildly glucose-intolerant and have 
less adipose tissue. Depending on strain and gender, these mice show either late 
loss of -cells followed by development of diabetes and mild growth deficiency, or 
compensatory increase of -cell mass without age-dependent progression into overt 
hyperglycaemia (Cho et al., 2001a, Garofalo et al., 2003). These studies suggested 
that only PKB plays a role in regulation of energy homeostasis. This view was 
recently challenged by a new study (Buzzi et al., 2010) that re-examined in parallel 
the metabolic phenotype of three mouse strains deficient for Pkb,  or , 
respectively. Here they confirmed that Pkb -/- mice are insulin resistant with 
compensatory increase of islet mass and that Pkb -/- mice show no metabolic 
abnormalities. However, Pkb -/- mice displayed improved insulin sensitivity, lower 
blood glucose and higher serum glucagon concentrations. These new findings 
prompted us to critically review the relevant literature on the metabolic role of PKB 
isoforms.  
 Protein Kinase B 
The PKB serine/threonine protein kinase family consists of three evolutionary 
conserved isoforms: PKB (AKT1), PKB (AKT2) and PKB (AKT3). PKB was first 
isolated from transforming murine leukemia virus AKT-8 by Staal et al in 1977, 
characterized as an oncogene and named akt (Staal et al., 1977). Two human 
homologues of the viral akt gene were identified later on and termed akt1 and akt2. 
In 1991, a human serine/threonine kinase was cloned, which was termed related to 
the A and C kinases (RAC) and subsequently renamed to PKB/Akt1 ((Jones et al., 
1991), reviewed in (Brazil and Hemmings, 2001)). Since the identification of PKB as 
a serine/threonine kinase, almost 20 years ago, PKB isoforms were studied 
intensively and are now considered as major regulators of elementary cellular 
process, such as proliferation, survival, cell growth and energy metabolism (Bozulic 
et al., 2008, Contreras-Ferrat et al., 2010, Haga et al., 2005, Heron-Milhavet et al., 
2006). Consequently, PKB isoforms play pivotal roles in physiology and their 
deregulation engenders diseases, such as cancer, neurodegeneration and metabolic 
disorders (Altomare and Testa, 2005, Zhao and Townsend, 2009). Remarkably, 
activation of PKB isoforms by gene amplification or mutations in upstream regulators 
frequently occurs in human cancers (Carpten et al., 2007). The molecular and cellular 
biology of PKB isoforms has been comprehensively reviewed (Brazil et al., 2002, 
Hanada et al., 2004, Manning and Cantley, 2007) and is therefore discussed only 
briefly in this review. 
PKB, PKB and PKB are encoded by three distinct genes, which are located on 
different chromosomes. In contrast to many members of other kinase families, PKB 
isoforms share the same protein structure and are approximately 80% identical at the 
amino acid level. They carry a N-terminal pleckstrin homology (PH) domain, a 
catalytic domain and a C-terminal regulatory domain (Hanada et al., 2004). PKB 
and PKB are ubiquitously expressed, whereas PKB expression is restricted to 
brain, testis, lung, fat, mammary glands and pancreatic islets (Buzzi et al., 2010, 
Yang et al., 2003). Low expression levels were also observed in skeletal muscle 
(Brozinick et al., 2003). Notably, expression of PKB and PKB is prominent in 
classical insulin target tissues involved in the regulation of systemic energy 
homeostasis, such as liver, skeletal muscle and fat (Yang et al., 2003). 
PKB isoforms are activated by growth factors and cytokines, including PDGF, VEGF, 
HGF, IGF-1, insulin, TNF and IL-2 but also by environmental stresses, such as heat 
shock, hypoxia and oxidative stress (Zhuravleva et al., 2010). Regulation of PKB 
downstream of these stimuli generally depends on activation of phosphatidyl-inositol 
3-kinase (PI3K) family members, which convert phosphatidy-inositol di-phosphate 
(PIP2) to PIP3 at the plasma membrane. PKB isoforms bind to PIP3 via their PH 
domain, which facilitates their activation. PKB isoforms are phosphorylated and 
thereby activated by upstream kinases at two distinct phosphorylation-sites. First, 
PDK1 phosphorylates PKB isoforms at the catalytic domain (Thr308 in PKB, Thr309 
in PKB and Thr305 in PKB) which results in basal kinase activity of approximately 
10%. In a second step, PKB isoforms are phosphorylated by mTORC2, DNA-PK or 
ATM at the C-terminal regulatory domain (Ser473 in PKB, Ser474 in PKB and 
Ser472 in PKB), which is essential for full kinase activity. Activation of PKB isoforms 
is tightly counter-regulated by phosphatases, such as PTEN and SHIP2. These 
phosphatases inactivate PIP3 by dephosphorylation and thereby prevent plasma 
membrane translocation and activation of PKB isoforms (Bhaskar and Hay, 2007, 
Brazil and Hemmings, 2001, Hanada et al., 2004, Zhuravleva et al., 2010). 
Activity of PKB isoforms is modulated by different binding partners, such as TRAF6, 
HSP90, CTMP and TCL1 which affect protein stability, dynamics and duration of 
activation and rate of kinase activity, respectively (Brazil et al., 2002). Furthermore, 
recent studies show that activity of PKB isoforms is indirectly modulated by several 
microRNAs. For instance, miR320 was shown to down-regulate PI3K in adipocytes 
resulting in inhibition of PKB activation and insulin resistance (Ling et al., 2009). 
However, it remains to be determined if modulation of PKB activity by binding 
partners and microRNAs plays a role in insulin signalling and regulation of glucose 
homeostasis. 
Upon activation, PKB isoforms are released from the plasma membrane and 
phosphorylate various substrates throughout the cell. PKB substrates can specifically 
regulate a single respective cellular process (e.g. cell survival, Bad or caspase 9), or 
pleiotropically affect several cellular functions simultaneously, such as Gsk3 and 
FoxO transcription factors which can control cell survival, proliferation but also energy 
metabolism (Manning and Cantley, 2007)  
The different phenotypes of Pkb -/-, Pkb -/- and Pkb -/- mice undoubtedly point to 
isoform-specific functions. As the expression of PKB isoforms overlaps in many 
organs, the different phenotypes can not solely be explained by divergent gene 
expression. There is an emerging number of studies describing isoform-specific 
functions in cellular processes, such as PKB in cancer cell migration (Chin and 
Toker, 2010), PKB in -cell proliferation and PKB in glucose uptake. Since PKB 
isoforms are structurally highly similar, including the kinase domain, it is unlikely that 
recognition of phosphorylation-motifs underlies substrate-specificity (Manning and 
Cantley, 2007). Therefore it is considered that substrate-specificity is controlled by 
cellular localization and specific binding partners. However, until today, functional 
differences of PKB isoforms at the cellular level are not yet fully characterized and 
the mechanisms determining substrate-specificity remain largely unknown. 
 
Liver 
The liver functions as a critical regulator of glucose homeostasis and the PI3K/PKB 
pathway co-ordinates hepatic glucose metabolism with the systemic metabolic state. 
Out of the three PKB isoforms, only PKB and PKB, but not PKB, are expressed in 
the liver. Studies using transgenic mice have shown, that PKB accounts for 
approximately 70% of total PKB protein in the liver and is therefore considered as the 
major isoform (Dummler et al., 2006). In hepatocytes, PKB and PKB are both 
activated upon insulin stimulation in a PI3K-dependent manner (Taniguchi et al., 
2006).  
According to the current model, insulin suppresses hepatic glucose output in several 
ways, including inhibition of gluconeogensis and stimulation of glycogen synthesis, 
which are both dependent on PKB activity (Newgard, 2003). Gluconeogenesis is 
suppressed after phosphorylation/inhibition of the transcription factor FoxO1, an 
inducer of gluconeogenic genes pepck and g6pase (Taniguchi et al., 2006). In 
addition, PKB also induces glycogen synthesis by phosphorylating and inhibiting 
GSK3 (Lawrence and Roach, 1997). Although it was shown that PKB (He et al., 
2010, Leavens et al., 2009) plays a critical role in these processes, the effects of 
endogenous PKB remain unclear. Furthermore, it was proposed that hepatic de 
novo lipogenesis is mainly regulated by PKC/, as expression of lipogenic genes, 
such as srebp-1c, is depended on PKC/ activity (Taniguchi et al., 2006). Even so, 
several studies show that PKB and PKB promote hepatic de novo lipogenesis as 
well (He et al., 2010, Leavens et al., 2009, Ono et al., 2003). 
The role of PKB activity in hepatic metabolism and its effects on systemic energy 
homeostasis was studied in mice with liver-specific deletions of major regulatory 
subunits of PI3K (pik3r1li/pik3r2li) and PTEN (ptenli) (Horie et al., 2004, Stiles et al., 
2004, Taniguchi et al., 2006). Insulin-stimulated activation of PKB, PKB and 
PKC/ was almost completely abrogated in pik3r1li/pik3r2li mice. Concomitantly, 
insulin also failed to downregulate hepatic gluconeogenesis and could no longer 
inhibit GSK3 and induce expression of lipogenic genes. As a consequence, 
pik3r1li/pik3r2li mice exhibited insulin resistance, hyperglycemia, hyperinsulinaemia 
and were glucose intolerant (Taniguchi et al., 2006). Remarkably, expression of 
gluconeogenic genes, pepck and g6pase was efficiently blocked after overexpression 
of constitutive active PKB (myr-PKB) whereas expression of lipogenic genes, 
srebp-1c, could only be restored by overexpression of constitutive active PKC/ 
(Taniguchi et al., 2006). On the other hand, gluconeogenic genes were down 
regulated and  phosphorylation of GSK3 and lipogenesis were enhanced in liver of 
ptenli mice, most likely due to hyper-activated PKB, PKB and PKC/. As a result, 
ptenli mice were found to be hypoglycaemic, hypoinsulinaemic, showed increased 
glucose tolerance and, most strikingly, developed hepatic steatosis with all 
characteristics of human non-alcoholic fatty liver disease (Horie et al., 2004, Stiles et 
al., 2004).  
In recent studies the role PKB in hepatic lipid accumulation was examined using 
different mouse models of hepatic steatosis (He et al., 2010, Leavens et al., 2009). 
Remarkably, whole-body deletion of pkb in ptenli, leptin-deficient (lepob/ob) and mice 
on high-fat diet (HFD) as well as liver-specific deletion of pkb in lepob/ob and mice on 
HFD significantly reduced lipid accumulation in hepatocytes. PKB-deficiency 
reduced expression of lipogenic genes and de novo lipogenesis, indicating that PKB 
is required for lipid accumulation in hepatocytes. 
Interestingly, pkb-deficiency had more pronounced effects in wildtype controls 
compared to ptenli mice. Therefore, increased activation of PKB, and possibly also 
of PKC/, might compensate for loss of PKB in hepatocytes. Indeed ectopic 
expression of constitutively active PKB (myr-PKB) in the liver induced 
hypoglycemia and hepatic steotosis, further supporting the notion for functional 
overlap between PKB and PKB in hepatocytes (Ono et al., 2003). However, 
activation of PKB isoforms by myristilation is rather artificial, and might induce non-
physiological functions.  
Notably, hepatic lipid content, but not de novo lipogenesis or expression of lipogenic 
genes, were reduced in PKBdeficient mice fed a specific HFD (Surwit diet, 
(Leavens et al., 2009)). Moreover, expression of myr-PKB upregulated srebp-1c in 
wildtype but not pik3r1li/pik3r2li mice and additionally promoted accumulation of 
hepatic lipids independent of srebp-1c (Ono et al., 2003, Taniguchi et al., 2006). 
These observations suggest that PKB and PKB regulate other processes in 
addition and that reduced lipogenesis could be a secondary effect dependent on 
PI3K/PKC. 
 
Skeletal muscle. 
Skeletal muscle is a specialised tissue that makes movement possible by 
transforming chemical energy into mechanical force. In addition, skeletal muscle is 
also central to metabolic regulation and 70-90% of glucose disposal during a 
hyperinsulinemic euglycaemic clamp occurs in this tissue (DeFronzo et al., 1981). 
Glucose taken up is mainly incorporated into glycogen (Shulman et al., 1990) and the 
majority (≈80%) of carbohydrates stored in humans are found in skeletal muscle 
(Jensen and Lai, 2009).  
It is the generally accepted view that insulin activates PKB via class 1A PI3K 
(Shepherd, 2005). Although this has not been conclusively shown in fully 
differentiated skeletal muscle, all available data support the view that PKB promotes 
insulin-stimulated glucose uptake and glycogen synthase activation (Cleasby et al., 
2007). Like in adipose tissue, glucose uptake is increased in skeletal muscle by 
triggering translocation of GLUT4 from intracellular vesicles to the plasma 
membrane, which depends on well studied signalling events downstream of the 
insulin receptor involving IRS, PKB and AS160. Skeletal muscle expresses all three 
PKB isoforms (Brozinick et al., 2003, Turinsky and Damrau-Abney, 1999) but only 
deletion of PKB causes insulin resistance and reduces insulin-stimulated glucose 
uptake (Cho et al., 2001a, Garofalo et al., 2003), indicating that PKB is required for 
this process. However, since high concentrations of insulin could still increase 
glucose disposal into muscle lacking PKB other signalling components might also 
be able to regulate GLUT4 translocation downstream of insulin. Indeed, 
overexpression of constitutively active PKB increases glucose uptake in L6 muscle 
cells (Hajduch et al., 1998) suggesting that PKB and PKB can both regulate 
translocation of GLUT4 to the plasma membrane. This finding is in line with the 
observation that insulin can activate all three isoforms of PKB in skeletal muscle 
(Brennesvik et al., 2005, Brozinick et al., 2003). Isoform-specific function has been 
investigated in several studies. Ectopic expression of constitutively active PKB or 
PKB in vivo in rat muscle fibres increased glycogen accumulation, but only 
expression of PKB increased basal glucose uptake (Cleasby et al., 2007). However, 
only PKB increased glycogen synthase kinase-3beta (GSK3) phosphorylation. 
Knockdown of PKBβ in fully differentiated muscle fibres by electrotransfer of short 
hairpin (sh)- RNAs decreased insulin-stimulated glucose uptake suggesting isoform-
specificity of PKB in regulation of glucose metabolism (Cleasby et al., 2007). 
Unfortunately, the role PKB was not addressed in this study. Interestingly, Brozinick 
et al. (Brozinick et al., 2003) found that insulin-stimulated PKBβ activation was 
reduced in insulin resistant muscles whereas insulin-stimulated activation of PKBα 
and PKBγ occurred normally. Evidence for isoform-specific signalling was provided 
by Bouzakri et al (Bouzakri et al., 2006). These authors could show that activation of 
PKB via IRS1 stimulates glucose uptake whereas IRS2-mediated activation of 
PKB increases lipid synthesis. 
Besides insulin, muscle contraction can also induce glucose uptake. Contraction-
induced glucose transport depends on increased translocation of GLUT4 but the 
underlying mechanism depends on AMPK and not on PI3K. However, contraction 
can increase PKB phosphorylation and activity (Sakamoto et al., 2003, Whitehead et 
al., 2000), but contraction-mediated PKB phosphorylation remains below 10% of 
insulin-stimulated PKB phosphorylation (Whitehead et al., 2000). Contraction 
increases activity of all isoforms, but PKB activation is most pronounced (Sakamoto 
et al., 2002). The notion that PKB does not mediate contraction-stimulated glucose 
uptake is in line with the fact that the PI3K inhibitor wortmannin does not inhibit 
contraction-stimulated glucose uptake (Whitehead et al., 2000). Accordingly, 
contraction-stimulated glucose transport is normal in skeletal muscle of PKB-
deficient mice (Sakamoto et al., 2006). Interestingly, contraction can block insulin-
stimulated class 1A PI3K activity without reducing insulin-stimulated PKB activation 
(Whitehead et al., 2000) indicating, that PKB phosphorylation might occur without 
increase in class 1A PI3K activity. This observation highlights the need to clarify 
which isoform(s) of PI3K mediate insulin-stimulated glucose uptake in skeletal 
muscle. 
 
Adipose tissue 
Insulin induces phosphorylation of PKB in adipocytes. Like in muscle and liver, the 
level of phosphorylation/activation of PKB after insulin stimulation is often regarded 
as benchmark for insulin sensitivity. This consensus is based on observations, that 
insulin resistance in adipose tissue is in many cases associated with less insulin-
induced phosphorylation of PKB and that increased or constitutive activation of PKB 
can increase or mimic insulin action, respectively. Many lines of evidence suggest, 
that mainly PKB is required downstream of insulin in adipocytes. For example, 
transient downregulation of PKB using siRNAs inhibits insulin-induced GLUT4 
translocation to the plasma membrane of 3T3-L1 adipocytes whereas knockdown of 
PKB did not result in any differences (Jiang et al., 2003, Katome et al., 2003). 
These findings are in line with the observation that Pkb -/- mice are insulin resistant 
whereas Pkb-/- mice are normal or even more insulin sensitive (Buzzi et al., 2010, 
Chen et al., 2001, Cho et al., 2001a, Cho et al., 2001b, Garofalo et al., 2003, Yang et 
al., 2003). However, not all metabolic functions regulated by insulin in adipocytes 
might be dependent on PKB alone, as described by Katome et al. (Katome et al., 
2003). These authors analysed 2-DG uptake and glycogen synthesis in 3T3-L1 
adipocytes after downregulation of PKB,  or  and found that PKB and PKB 
contributed to insulin-stimulated glycogen synthesis to about the same extent while 2-
DG uptake only depended on PKB. Accordingly, insulin appears to stimulate the 
association of PKB with GLUT4-containing vesicles in rat adipocytes (Calera et al., 
1998) and overexpression of PKB, but not PKB, rescues impaired glucose 
transport in PKB-deficient adipocytes (Bae et al., 2003). How isoform-specificity 
might be achieved in adipocytes was studied by Gonzales and McGraw (Gonzalez 
and McGraw, 2009). These authors found that insulin activates both PKB and PKB 
in adipocytes, but describe differential subcellular distribution of these two isoforms 
upon stimulation. While basally adipocytes had similar levels of PKB and PKB at 
the plasma membrane, a significantly greater fraction of PKB accumulated at the 
plasma membrane after stimulation with insulin. The question if PKB plays a role in 
lipogenesis has received surprisingly little attention. However, Berggreen and 
colleagues (Berggreen et al., 2009) recently described that inhibition of PKB in 3T3-
L1 adipocytes with an inhibitor called Akti reduced de novo and insulin-dependent 
lipid synthesis and that insulin failed to regulate the rate-limiting lipogenic enzyme 
acetyl-CoA carboxylase (ACC) when PKB was inhibited. Specific roles for the 
different isoforms of PKB were not described in this study.  
Interestingly, there is a small but noteworthy number of studies with conflicting 
results. For example, Kitamura et al.(Kitamura et al., 1998) expressed a dominant-
negative PKB isoform (Akt-AA) in 3T3-L1 adipocytes. This isoform contains two 
alanines instead of the two regulated phosphorylation sites (Thr308 and Ser473) and 
its expression reduced activation of PKB by about 80-95%. Expression of Akt-AA 
inhibited insulin-dependent protein synthesis without affecting glucose transport 
indicating, that PKB might only be required for some but not all effects of insulin in 
adipocytes. Similarly, Guilherme and Czech (Guilherme and Czech, 1998) presented 
evidence that the formation of IRS1/PI3K complexes and Akt/PKB activation are 
insufficient to stimulate glucose transport in rat adipocytes. At least two more recent 
studies also describe that insulin-dependent activation of PKB does not necessarily 
correlate with insulin-induced 2-DG transport (Hoehn et al., 2008, Xu et al., 2010). 
Finally, Buzzi et al. (Buzzi et al., 2010) found that primary adipocytes isolated from 
Pkb-deficient mice show higher insulin-induced glucose incorporation than 
adipocytes from wild type littermates.  
 
Pancreatic islets 
To proper regulate blood glucose homeostasis islet mass and function has to be 
coordinated with metabolic demand. Plasticity of islet mass is achieved by integration 
of a complex signal environment comprised of nutrients, hormones and cytokines that 
controls the balance between apoptosis and cell growth/proliferation (Maedler, 2008, 
Niessen, 2006). Because PKB is a global regulator of growth, proliferation and 
apoptosis, it has been implicated to play a major role in modulating plasticity of islet 
mass downstream of insulin receptor substrate 2 (IRS2) (Elghazi et al., 2007, 
Hennige et al., 2003, Kubota et al., 2000, Lingohr et al., 2003, Mohanty et al., 2005, 
Park et al., 2006, Takamoto et al., 2008, Withers et al., 1998, Wrede et al., 2002). 
Yet, a number of studies addressing this issue yielded somewhat unexpected results. 
Pkb-deficient mice show impaired placental development and foetal growth (Buzzi 
et al., 2010, Chen et al., 2001, Tuttle et al., 2001, Yang et al., 2003) but normal islet 
growth and function. pkb-deficient mice show impaired overall growth but display, 
dependent on strain and sex, even compensatory increase in -cell mass (Buzzi et 
al., 2010, Cho et al., 2001a, Garofalo et al., 2003). Finally, pkb-deficient mice 
display reduction in brain size without any distortions of islet function or mass (Buzzi 
et al., 2010, Easton et al., 2005, Tschopp et al., 2005). In another study -cell-
specific loss of function for PKB was induced by expression of a kinase-dead 
dominant-negative form of PKB (rip-kdpkb), however, only defective insulin 
secretion but no reduction in islet size was observed (Bernal-Mizrachi et al., 2004). 
Since the dominant-negative form antagonizes all three isoforms this latter finding 
makes compensation between isoforms an unlikely explanation for the normal islet 
phenotypes of PKB-deficient mice. In contrast to the loss of function phenotype, 
ectopic expression of constitutively active PKB under the control of the rat insulin 
promoter (rip) (Bernal-Mizrachi et al., 2001, Tuttle et al., 2001) resulted in 
hypertrophy and hyperplasia of islets. Such mice were hyperinsulinaemic and 
resistant to streptozotocin-induced diabetes. Taken together the results from these 
mouse models suggest that although none of the PKB isoforms is required for 
maintenance of islet mass, constitutive activation of at least PKB is sufficient to 
increase islet size. In order to reconcile these observations it was proposed (Niessen, 
2006) that maintenance and compensatory expansion of islet mass (as observed in 
insulin resistance) do not depend on the same signal transduction pathways 
downstream of IRS2. This model predicts that PKB is only required for expansion but 
not for maintenance of islet mass. Which of the three PKB isoforms is/are required to 
regulate islets mass was studied recently by Buzzi et al. (Buzzi et al., 2010). This 
study shows that only PKB, but not PKB or , is specifically activated downstream 
of IRS2 in -cells. Furthermore, adenoviral overexpression of PKB increased 
proliferation of -cells while overexpression of the remaining two isoforms was 
ineffective, indicating that PKB is in control of the regulation of -cell mass. 
 
Perspectives and conclusions 
Insulin sensitivity manifests at the signalling level and at the level of cellular function. 
Since the insulin receptor is present on many, if not all, mammalian cells the 
biological function of insulin is cell type-specific, and, within a given cell type, insulin 
often controls more than one cellular process. For example, insulin induces GLUT4-
dependent transport and deposition of glucose into fat. It also inhibits lipolysis. The 
analysis of any of these endpoints after stimulation with insulin allows unambiguous 
determination of how insulin sensitive the target cell is for the respective function. It 
has become common practice in the field to correlate insulin-induced cellular effects 
with intra-cellular insulin signal transduction, however, insulin sensitivity at the 
signalling level is not easy to measure because the insulin receptor connects to an 
intricate and highly context-specific intra-cellular network of signalling molecules. In 
practice insulin-dependent activation of few protein kinases within this network is 
usually correlated with specific insulin-induced cellular responses. PKB is regarded 
as most important mediator of metabolic insulin action and its activation is often 
monitored by using phospho-specific antibodies in combination with Western blotting. 
However, as described in this review, insulin signalling might branch at the level of 
PKB isoforms to control different aspects of metabolic regulation but in most of the 
cases, the possibility for non-redundant roles of PKB isoforms is not taken into 
consideration. Technically, due to high conservation of the aminoacid sequence 
surrounding the phosphorylated Ser and Thr residues in the three isoforms, none of 
the available phospho-specific antibodies can be used to determine which isoform(s) 
is(are) activated without prior isoform-specific immunoprecipitation. As more and 
more evidence for specific and possibly even opposing roles of PKB isoforms 
accumulates it appears justified to reconsider the appropriateness of detecting PKB 
phoshphorylation to assess overall insulin sensitivity without consideration of the 
specific isoform.  
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